The hemodynamic effects of propofol in children with congenital heart disease

Glyn D. Williams, Thomas K. Jones, Kimberly A. Hanson, Jeffrey P. Morray

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

We studied the hemodynamic effects of propofol during elective cardiac catheterization in 30 children with congenital heart disease. Sixteen patients were without cardiac shunt (Group I), six had left-to-right cardiac shunt (Group II), and eight had right-to-left cardiac shunt (Group III). The mean (±SD) ages were 3.8 ± 3.1 yr (Group I), 3.2 ± 3.7 yr (Group II), and 1.0 ± 0.6 yr (Group III). After sedation and cardiac catheter insertion, hemodynamic data and oxygen consumption were measured before and after the administration of propofol (2-mg/kg bolus, 50- to 200-μg · kg-1 · min- 1 infusion), and values were compared by using a paired t-test (significance: P < 0.05). After the propofol administration, systemic mean arterial pressure and systemic vascular resistance decreased significantly and systemic blood flow increased significantly in all patient groups; heart rate, pulmonary mean arterial pressure, and pulmonary vascular resistance were unchanged. Pulmonary to systemic resistance ratio increased (Group I, P = 0.005; Group II, P = 0.03; Group III, P = 0.10). In patients with cardiac shunt, propofol resulted in decreased left-to-right flow and increased right- to-left flow; the pulmonary to systemic flow ratio decreased significantly (Group II, P = 0.005; Group III, P = 0.01). Clinically relevant decreases in PaO2 (P = 0.008) and SaO2 (P = 0.01) occurred in Group III patients. We conclude that propofol can result in clinically important changes in cardiac shunt direction and flow. Implications: The principal hemodynamic effect of propofol in children with congenital heart defects is a decrease in systemic vascular resistance. In children with cardiac shunt, this results in a decrease in the ratio of pulmonary to systemic blood flow, and it can lead to arterial desaturation in patients with cyanotic heart disease.

Original languageEnglish (US)
Pages (from-to)1411-1416
Number of pages6
JournalAnesthesia and analgesia
Volume89
Issue number6
StatePublished - Dec 1 1999

Fingerprint

Propofol
Heart Diseases
Hemodynamics
Vascular Resistance
Lung
Arterial Pressure
Cardiac Catheters
Congenital Heart Defects
Cardiac Catheterization
Oxygen Consumption
Heart Rate

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

The hemodynamic effects of propofol in children with congenital heart disease. / Williams, Glyn D.; Jones, Thomas K.; Hanson, Kimberly A.; Morray, Jeffrey P.

In: Anesthesia and analgesia, Vol. 89, No. 6, 01.12.1999, p. 1411-1416.

Research output: Contribution to journalArticle

Williams, GD, Jones, TK, Hanson, KA & Morray, JP 1999, 'The hemodynamic effects of propofol in children with congenital heart disease', Anesthesia and analgesia, vol. 89, no. 6, pp. 1411-1416.
Williams, Glyn D. ; Jones, Thomas K. ; Hanson, Kimberly A. ; Morray, Jeffrey P. / The hemodynamic effects of propofol in children with congenital heart disease. In: Anesthesia and analgesia. 1999 ; Vol. 89, No. 6. pp. 1411-1416.
@article{acc346202a5844198d81221bacca0fb0,
title = "The hemodynamic effects of propofol in children with congenital heart disease",
abstract = "We studied the hemodynamic effects of propofol during elective cardiac catheterization in 30 children with congenital heart disease. Sixteen patients were without cardiac shunt (Group I), six had left-to-right cardiac shunt (Group II), and eight had right-to-left cardiac shunt (Group III). The mean (±SD) ages were 3.8 ± 3.1 yr (Group I), 3.2 ± 3.7 yr (Group II), and 1.0 ± 0.6 yr (Group III). After sedation and cardiac catheter insertion, hemodynamic data and oxygen consumption were measured before and after the administration of propofol (2-mg/kg bolus, 50- to 200-μg · kg-1 · min- 1 infusion), and values were compared by using a paired t-test (significance: P < 0.05). After the propofol administration, systemic mean arterial pressure and systemic vascular resistance decreased significantly and systemic blood flow increased significantly in all patient groups; heart rate, pulmonary mean arterial pressure, and pulmonary vascular resistance were unchanged. Pulmonary to systemic resistance ratio increased (Group I, P = 0.005; Group II, P = 0.03; Group III, P = 0.10). In patients with cardiac shunt, propofol resulted in decreased left-to-right flow and increased right- to-left flow; the pulmonary to systemic flow ratio decreased significantly (Group II, P = 0.005; Group III, P = 0.01). Clinically relevant decreases in PaO2 (P = 0.008) and SaO2 (P = 0.01) occurred in Group III patients. We conclude that propofol can result in clinically important changes in cardiac shunt direction and flow. Implications: The principal hemodynamic effect of propofol in children with congenital heart defects is a decrease in systemic vascular resistance. In children with cardiac shunt, this results in a decrease in the ratio of pulmonary to systemic blood flow, and it can lead to arterial desaturation in patients with cyanotic heart disease.",
author = "Williams, {Glyn D.} and Jones, {Thomas K.} and Hanson, {Kimberly A.} and Morray, {Jeffrey P.}",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "89",
pages = "1411--1416",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The hemodynamic effects of propofol in children with congenital heart disease

AU - Williams, Glyn D.

AU - Jones, Thomas K.

AU - Hanson, Kimberly A.

AU - Morray, Jeffrey P.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - We studied the hemodynamic effects of propofol during elective cardiac catheterization in 30 children with congenital heart disease. Sixteen patients were without cardiac shunt (Group I), six had left-to-right cardiac shunt (Group II), and eight had right-to-left cardiac shunt (Group III). The mean (±SD) ages were 3.8 ± 3.1 yr (Group I), 3.2 ± 3.7 yr (Group II), and 1.0 ± 0.6 yr (Group III). After sedation and cardiac catheter insertion, hemodynamic data and oxygen consumption were measured before and after the administration of propofol (2-mg/kg bolus, 50- to 200-μg · kg-1 · min- 1 infusion), and values were compared by using a paired t-test (significance: P < 0.05). After the propofol administration, systemic mean arterial pressure and systemic vascular resistance decreased significantly and systemic blood flow increased significantly in all patient groups; heart rate, pulmonary mean arterial pressure, and pulmonary vascular resistance were unchanged. Pulmonary to systemic resistance ratio increased (Group I, P = 0.005; Group II, P = 0.03; Group III, P = 0.10). In patients with cardiac shunt, propofol resulted in decreased left-to-right flow and increased right- to-left flow; the pulmonary to systemic flow ratio decreased significantly (Group II, P = 0.005; Group III, P = 0.01). Clinically relevant decreases in PaO2 (P = 0.008) and SaO2 (P = 0.01) occurred in Group III patients. We conclude that propofol can result in clinically important changes in cardiac shunt direction and flow. Implications: The principal hemodynamic effect of propofol in children with congenital heart defects is a decrease in systemic vascular resistance. In children with cardiac shunt, this results in a decrease in the ratio of pulmonary to systemic blood flow, and it can lead to arterial desaturation in patients with cyanotic heart disease.

AB - We studied the hemodynamic effects of propofol during elective cardiac catheterization in 30 children with congenital heart disease. Sixteen patients were without cardiac shunt (Group I), six had left-to-right cardiac shunt (Group II), and eight had right-to-left cardiac shunt (Group III). The mean (±SD) ages were 3.8 ± 3.1 yr (Group I), 3.2 ± 3.7 yr (Group II), and 1.0 ± 0.6 yr (Group III). After sedation and cardiac catheter insertion, hemodynamic data and oxygen consumption were measured before and after the administration of propofol (2-mg/kg bolus, 50- to 200-μg · kg-1 · min- 1 infusion), and values were compared by using a paired t-test (significance: P < 0.05). After the propofol administration, systemic mean arterial pressure and systemic vascular resistance decreased significantly and systemic blood flow increased significantly in all patient groups; heart rate, pulmonary mean arterial pressure, and pulmonary vascular resistance were unchanged. Pulmonary to systemic resistance ratio increased (Group I, P = 0.005; Group II, P = 0.03; Group III, P = 0.10). In patients with cardiac shunt, propofol resulted in decreased left-to-right flow and increased right- to-left flow; the pulmonary to systemic flow ratio decreased significantly (Group II, P = 0.005; Group III, P = 0.01). Clinically relevant decreases in PaO2 (P = 0.008) and SaO2 (P = 0.01) occurred in Group III patients. We conclude that propofol can result in clinically important changes in cardiac shunt direction and flow. Implications: The principal hemodynamic effect of propofol in children with congenital heart defects is a decrease in systemic vascular resistance. In children with cardiac shunt, this results in a decrease in the ratio of pulmonary to systemic blood flow, and it can lead to arterial desaturation in patients with cyanotic heart disease.

UR - http://www.scopus.com/inward/record.url?scp=0032701851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032701851&partnerID=8YFLogxK

M3 - Article

C2 - 10589618

AN - SCOPUS:0032701851

VL - 89

SP - 1411

EP - 1416

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -